These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 15634527

  • 1. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
    Liu SW, Yu JM, Xing LG.
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
    [Abstract] [Full Text] [Related]

  • 2. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J, Milleron B, Vaylet F, Grahek D, Lebeau B, Mangiapan G, Bonardel G, de Labriolle-Vaylet C, Meignan M, Carette MF, Talbot JN, Housset B.
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [Abstract] [Full Text] [Related]

  • 3. 18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of Non-Small Cell Lung Cancer: A Prospective Study.
    Promteangtrong C, Kunawudhi A, Phadungrerk R, Iamsa-art C, Chotipanich C.
    J Med Assoc Thai; 2015 Oct; 98(10):1010-8. PubMed ID: 26638593
    [Abstract] [Full Text] [Related]

  • 4. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
    Guan Y, He S, Dong J.
    Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705
    [Abstract] [Full Text] [Related]

  • 5. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF, Liu Y, Zhang JH, Zhou RS, Zhou FH, Yuan MH.
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [Abstract] [Full Text] [Related]

  • 6. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Scheiderbauer J, Budach W, Kotzerke J, Bares R.
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic impact of integrated 18F-FDG PET/MRI in cerebral staging of patients with non-small cell lung cancer.
    Deuschl C, Nensa F, Grueneisen J, Poeppel TD, Sawicki LM, Heusch P, Gramsch C, Mönninghoff C, Quick HH, Forsting M, Umutlu L, Schlamann M.
    Acta Radiol; 2017 Aug; 58(8):991-996. PubMed ID: 28273734
    [Abstract] [Full Text] [Related]

  • 8. Value of positron emission tomography for lung cancer staging.
    Albes JM, Dohmen BM, Schott U, Schülen E, Wehrmann M, Ziemer G.
    Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
    [Abstract] [Full Text] [Related]

  • 9. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, Seki H, Taki S, Tonami H, Yamamoto I.
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [Abstract] [Full Text] [Related]

  • 10. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
    Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, Hogg A, Ball DL.
    J Clin Oncol; 2001 Jan 01; 19(1):111-8. PubMed ID: 11134203
    [Abstract] [Full Text] [Related]

  • 11. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment.
    Mac Manus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salminen E, Khaw P, Wirth A, Rischin D, McKenzie A.
    Cancer; 2001 Aug 15; 92(4):886-95. PubMed ID: 11550162
    [Abstract] [Full Text] [Related]

  • 12. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC.
    Eur J Nucl Med Mol Imaging; 2017 Jan 15; 44(1):8-16. PubMed ID: 27600280
    [Abstract] [Full Text] [Related]

  • 13. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
    Deniaud-Alexandre E, Touboul E, Lerouge D, Grahek D, Foulquier JN, Petegnief Y, Grès B, El Balaa H, Keraudy K, Kerrou K, Montravers F, Milleron B, Lebeau B, Talbot JN.
    Int J Radiat Oncol Biol Phys; 2005 Dec 01; 63(5):1432-41. PubMed ID: 16125870
    [Abstract] [Full Text] [Related]

  • 14. Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy--a retrospective study.
    Abramyuk A, Appold S, Zöphel K, Hietschold V, Baumann M, Abolmaali N.
    Lung Cancer; 2012 Nov 01; 78(2):148-52. PubMed ID: 22922126
    [Abstract] [Full Text] [Related]

  • 15. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C, Ceresoli GL, Rizzo G, Artioli D, Cattaneo M, Castellone P, Gregorc V, Picchio M, Landoni C, Fazio F.
    Q J Nucl Med Mol Imaging; 2005 Sep 01; 49(3):259-66. PubMed ID: 16172572
    [Abstract] [Full Text] [Related]

  • 16. Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT?
    Schaarschmidt BM, Grueneisen J, Metzenmacher M, Gomez B, Gauler T, Roesel C, Heusch P, Ruhlmann V, Umutlu L, Antoch G, Buchbender C.
    Eur Radiol; 2017 Feb 01; 27(2):681-688. PubMed ID: 27180186
    [Abstract] [Full Text] [Related]

  • 17. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, Choi JY, Kwon OJ, Shim YM, Kim S.
    Radiology; 2005 Sep 01; 236(3):1011-9. PubMed ID: 16014441
    [Abstract] [Full Text] [Related]

  • 18. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
    Weber WA, Dietlein M, Hellwig D, Kirsch CM, Schicha H, Schwaiger M.
    Nuklearmedizin; 2003 Aug 01; 42(4):135-44. PubMed ID: 12937692
    [Abstract] [Full Text] [Related]

  • 19. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C, Sonmezoglu K, Toker A, Yilmazbayhan D, Dilege S, Halac M, Erelel M, Ece T, Mudun A.
    Clin Nucl Med; 2007 Aug 01; 32(8):607-12. PubMed ID: 17667432
    [Abstract] [Full Text] [Related]

  • 20. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
    Kim MP, Correa AM, Hofstetter W, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Erasmus JJ, Swisher SG.
    Ann Thorac Surg; 2015 Feb 01; 99(2):414-20. PubMed ID: 25497068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.